In the fully adjusted models, initiation of OHG medications had a HR of 1.39 (95% CI, 0.86–2.27) and insulin had a HR of 2.84 (95% CI, 1.58–5.12) for developing pancreatic cancer. The gene discussed is INS; the disease is familial pancreatic carcinoma.